Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4166/kjg.2014.63.4.199 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Predictive factors influencing hypothyroidism following the radioactive iodine treatment of Graves' disease in different periods.
Sci Rep
December 2024
Department of Nuclear Medicine, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, 710061, Shaanxi, People's Republic of China.
In China, due to the risks of hypothyroidism after radioiodine treatment, radioiodine is not commonly used as a first-line treatment. In this study, factors influencing the development of hypothyroidism after I therapy for Graves' hyperthyroidism were evaluated. This was a retrospective study with a 12-month follow-up.
View Article and Find Full Text PDFUrsodeoxycholic acid (UDCA) is the first-line treatment for primary biliary cholangitis (PBC), but 20-40% of patients do not respond well to UDCA. We aimed to develop and validate a prognostic model for the early prediction of patients who nonresponse to UDCA. This retrospective analysis was conducted among patients with primary biliary cholangitis(N = 257) to develop a predictive model for early-stage nonresponse to ursodeoxycholic acid (UDCA) therapy.
View Article and Find Full Text PDFCeftazidime-avibactam for the treatment of febrile neutropenia in HSCT recipients and acute leukemia patients post induction chemotherapy.
Sci Rep
December 2024
American University of Beirut, Cairo Street, Riad El Solh, PO Box 11-0236/11D, Beirut, 1107 2020, Lebanon.
Febrile neutropenia is a major complication in patients with acute leukemia or those undergoing hematopoietic stem cell transplantation (HSCT). Understanding patient characteristics and susceptibility patterns in febrile neutropenia is essential for appropriate antimicrobial therapy. First-line agents should have Pseudomonas aeruginosa coverage, but with the increase in multi-drug resistant organisms, ceftazidime-avibactam has emerged as a new therapeutic option.
View Article and Find Full Text PDFPharmacological blockade of infection chronification modulates oxy-inflammation and prevents the activation of stress-induced premature senescence markers in schistosomiasis.
Microb Pathog
December 2024
Departamento de Biologia Animal (DBA), Programa de Pós-Graduação em Biologia Animal (PPGBA), Universidade Federal de Viçosa (UFV), Viçosa, 36570-900, Minas Gerais, Brazil.
Chronic inflammation, oxidative stress, and DNA damage are observed in schistosomiasis and premature aging. However, the potential of these events to trigger stress-induced premature senescence (SIPS) throughout schistosomiasis progression remains overlooked, especially in response to the first-line pharmacological treatment. Thus, we investigated the relationship between oxidative stress and SIPS sentinel markers in untreated Schistosoma mansoni-infected mice and those receiving praziquantel (Pz)-based reference treatment.
View Article and Find Full Text PDFComparative efficacy and safety of treatment regimens for Pneumocystis jirovecii pneumonia in people living with HIV - A systematic review and network meta-analysis of randomized controlled trials.
Clin Microbiol Infect
December 2024
BioTechMed-Graz, Graz, Austria; Division of Infectious Diseases, Department of Internal Medicine, Medical University of Graz, Graz, Austria. Electronic address:
Background: Pneumocystis jirovecii pneumonia (PCP) is a serious opportunistic infection in people living with HIV (PWH) who have low CD4 counts. Despite its side effects, trimethoprim-sulfamethoxazole (TMP-SMX) is currently considered the primary treatment for PCP.
Objectives: To compare the efficacy (treatment-failure and mortality) and tolerability (treatment change) of PCP treatment-regimens with a frequentist network meta-analysis (NMA).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!